TradeFlare's AI research teams analysed VERA on 8 market nights between April 16, 2026 and July 20, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 20, 2026 | BUY | $38.50 | $46.20 / $32.73 | -4.9% | -14.5% | The FDA approval provides a clear catalyst for potential upside over the coming weeks. |
| July 17, 2026 | BUY | $39.12 | — / — | -7.9% | -17.8% | The stock is consolidating near resistance with conflicting technical signals, requiring further price action confirmation. |
| July 16, 2026 | BUY | $42.50 | — / — | -7.1% | -26.1% | FDA accelerated approval of TRUTAKNA™ for IgA nephropathy. |
| July 13, 2026 | BUY | $42.00 | $51.59 / $35.70 | -10.9% | -23.9% | The FDA approval catalyst suggests a medium-term upward trend. |
| July 10, 2026 | BUY | $42.45 | $49.80 / $35.28 | -8.3% | -21.7% | The FDA approval provides a clear catalyst, and the technical setup suggests a potential breakout. |
| July 9, 2026 | BUY | $42.43 | $46.93 / $36.06 | -7.8% | -24.6% | The FDA approval provides a near-term catalyst, but the stock's high risk profile suggests a shorter-term trading horizon. |
| June 25, 2026 | BUY | $39.51 | $45.00 / $31.88 | +1.7% | -12.5% | The post-earnings drift signal suggests a multi-week upward trend. |
| April 16, 2026 | BUY | $43.45 | $49.72 / $39.95 | -9.1% | -6.3% | Based on the potential for price movement towards resistance levels in the coming weeks. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.